Topic: Johnson & Johnson

Rivaroxaban Significantly Reduces Risk of Stroke in Patients With Atrial Fibrillation With Comparable Safety vs. Warfarin in Pivotal Phase 3 Study

Drugs.com - 464 days ago
Results Presented as a Late-Breaker at the Scientific Sessions of the American Heart Association. Johnson & Johnson Pharmaceutical & Development, L.L.C. announced today that results from the pivotal Phase 3 double-blind ROCKET AF trial showed rivaroxaban given once daily was superior in ...

Wi-Fi pacemaker can call doctor at 2AM

TechRadar UK - 925 days ago
A woman in the US has been implanted with a Wi-Fi pacemaker to help doctors monitor her condition more effectively.. While the latter is still necessary, the doctor has most of the information available to him already, meaning the appointment time is ...